Biomedical Application of Nanoparticles explores nanoparticles, their chemical and physicals properties, and how they interact in biological systems with proteins, immune system and targeted cells. Risk assessment of nanoparticles for human is described, including: cellular paradigms, transcriptomics and toxicogenomics. Finally, the applications of nanoparticles in medicine and antioxidant regenerative therapeutics are presented in several chapters with emphasis on how nanoparticles enhance transport of drugs across biological membrane barriers and therefore may enhance drug bioavailability.
| Foreword |
|
ix | |
| Series Preface: Oxidative Stress in Health and Disease |
|
xi | |
| Editor |
|
xiii | |
| Contributors |
|
xv | |
|
SECTION I Nanoparticle Characterization |
|
|
|
Chapter 1 Nanoparticle World: History and Introduction to Their Diversity in Medicine |
|
|
3 | (20) |
|
|
|
Chapter 2 Dispersion and Characterization of Nanoparticles |
|
|
23 | (30) |
|
|
|
|
|
|
|
Chapter 3 Nanomedicine Clinical and Preclinical Use: A Status Report |
|
|
53 | (44) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chapter 4 Green Synthesis and Characterization of Semiconductor and Metal Nanoparticles |
|
|
97 | (16) |
|
|
|
Oluwatobi Samuel Oluwafemi |
|
|
SECTION II Interaction with Biological Systems |
|
|
|
Chapter 5 The Nanoparticle "Coronome" Is Mainly Explained by InterPro Domains of Proteins |
|
|
113 | (20) |
|
|
|
|
|
|
|
Chapter 6 Nanoparticles and Viruses as Mitophagy Inducers in Immune Cells |
|
|
133 | (30) |
|
|
|
|
|
|
|
|
|
SECTION III Safety Assessment for Human Use |
|
|
|
Chapter 7 Rodent Inhalation Studies in Nanomaterial Risk Assessment |
|
|
163 | (26) |
|
|
|
|
|
|
|
Chapter 8 In Vivo Evaluation of the Hepatonephrotoxicity of Polymeric Nanoparticles in Rats |
|
|
189 | (20) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chapter 9 In Vitro Exposure Systems to Assess the Toxicity of Airborne Substances |
|
|
209 | (14) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Chapter 10 Nanoparticles as Nitroso-Glutathion Vehicles |
|
|
223 | (14) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chapter 11 Transbarrier Trafficking of Nanoparticles: Perspectives for Cancer Therapeutics |
|
|
237 | (40) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Chapter 12 Polymeric Nanoparticles as a Vehicle for Delivery of Antioxidants in the Brain: Potential Application in Neurodegenerative Diseases |
|
|
277 | (24) |
|
|
|
|
|
|
|
Chapter 13 Application of Nanomaterials in Photodynamic Therapy |
|
|
301 | (12) |
|
|
|
|
|
|
|
Oluwatobi Samuel Oluwafemi |
|
|
Chapter 14 Nanomedicine: A Complex Interplay between Patients, Science, and Society |
|
|
313 | (10) |
|
|
|
|
|
|
| Index |
|
323 | |
Bertrand Henri Rihn, MD, DSc, professor of biochemistry and molecular biol-ogy at Lorraine University, France, is a leading expert in the field of particulate toxicology, with research topics including safety toxicology, immunotoxicology, and investigating the transcriptomic changes in macrophages following nanopar-ticle exposure. In addition to his research, Professor Rihn has also worked as a clinical toxicologist, and was awarded the Baratz Award (2004) and the E. Taub Award (2011) from the National Academy of Medicine (France). He also served as the president of the French Society of Toxicology from 2007 to 2009, and was a EUROTOX Registered Toxicologist.
